PTSD and Alcohol Use Disorder: Co-Occurrence, Mechanisms, and Integrated Treatment

Overview

Post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are two of the most common and disabling mental health conditions in the world — and they occur together far more often than chance would predict. When they do, the combination is not simply "two problems at once." The evidence shows that PTSD and AUD interact in ways that amplify each other, worsen outcomes, and dramatically increase the risk of suicide. Understanding this relationship — and treating both conditions at the same time — is one of the most important priorities in modern psychiatry.

For decades, many clinicians operated under a "get sober first" rule: stabilize the drinking before touching the trauma. That model is now outdated. A growing body of research supports integrated treatment — addressing PTSD and AUD simultaneously — as both feasible and effective. The evidence does not show that trauma processing destabilizes recovery. In fact, leaving trauma untreated is often what drives relapse.

This article synthesizes the current evidence base on PTSD-AUD comorbidity, covering who is affected, why the two disorders reinforce each other, what treatments work, and where the field still has important gaps to fill.

Epidemiology

The co-occurrence of PTSD and AUD is well-documented across populations, settings, and countries. In Danish substance use disorder treatment settings, approximately 25% of individuals met criteria for probable PTSD ^[1]. In a large Japanese population survey of 5,150 trauma-exposed adults, PTSD was associated with an odds ratio of 2.02 (95% CI: 1.62–2.52) for AUD compared to trauma-unexposed individuals — meaning people with PTSD were roughly twice as likely to develop AUD ^[2] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Trauma exposure alone, even without a PTSD diagnosis, still elevated AUD odds (OR = 1.55), suggesting that the trauma itself carries risk independent of whether it produces a full PTSD syndrome ^[2].

Among first responders, research using latent profile analysis has identified distinct comorbidity clusters in which PTSD, depression, AUD, and insomnia co-cluster in severity-correlated patterns — meaning the more severe the PTSD, the more severe the AUD and the other conditions alongside it ^[2]. Trauma count, anger, and low resilience have been found to drive membership in higher-symptom profiles.

Veterans represent a population with particularly elevated risk. Veterans are at increased risk of comorbid PTSD and AUD relative to civilians ^[2], and among post-9/11 veterans, higher or fluctuating alcohol use trajectories were linked to elevated risk of cognitive diagnoses (hazard ratios 1.21–1.42) even after accounting for traumatic brain injury and PTSD ^[3].

Population-level data underscore the synergistic danger of this comorbidity: comorbid PTSD and AUD has been associated with substantially elevated rates of non-fatal suicide attempts beyond what either disorder alone predicts, after adjusting for major depression and other covariates ^[4] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This is not an additive risk — it is synergistic. The interaction between PTSD and AUD creates a level of danger that neither condition produces on its own. Females whose PTSD preceded AUD carried the highest comorbidity burden; AUD-first sequencing showed larger main effects overall ^[4] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This population-level evidence is among the strongest arguments for why these two conditions must be treated together, urgently.

The Bidirectional Relationship

PTSD and AUD do not simply co-occur — they actively worsen each other through multiple pathways that run in both directions.

PTSD can lead to AUD. People living with PTSD experience hyperarousal, intrusive memories, nightmares, emotional numbing, and persistent fear. Alcohol provides rapid, pharmacologically real relief from these symptoms. It reduces anxiety through GABA-mediated mechanisms, blunts the startle response, and can temporarily suppress nightmares. For someone who cannot sleep, cannot stop reliving a traumatic event, and cannot quiet their nervous system, alcohol works — at least in the short term. This is the foundation of the self-medication hypothesis, discussed in detail below.

AUD can lead to PTSD. Intoxication increases exposure to traumatic events — accidents, violence, assault. Alcohol also impairs the brain's ability to process and consolidate memories, which may interfere with the natural emotional processing that helps people recover from trauma. Animal model data demonstrate that early alcohol exposure worsens fear extinction deficits through hippocampal synaptic damage ^[5], providing a neurobiological mechanism for why heavy drinking may make PTSD harder to recover from. Neuroimaging studies in humans with comorbid PTSD and alcohol dependence have identified significant deactivations in visual processing and memory regions (left middle occipital gyri, right lingual gyri) compared to PTSD alone ^[6], suggesting the combination produces distinct neural signatures beyond either disorder separately.

Each disorder maintains the other. Untreated PTSD symptoms — particularly hyperarousal and emotional dysregulation — are among the strongest predictors of relapse in people trying to reduce their drinking. Conversely, continued heavy drinking prevents the emotional processing that trauma recovery requires, and alcohol withdrawal itself produces anxiety and hyperarousal that can mimic and amplify PTSD symptoms. The result is a self-reinforcing cycle that neither "treat the PTSD first" nor "treat the AUD first" approaches can fully interrupt.

Research on PTSD symptom clusters adds important nuance. Dysphoric arousal and externalizing behaviors are the PTSD symptom dimensions most strongly linked to AUD in veterans [corpus-gap] — suggesting that not all PTSD symptoms carry equal weight in driving alcohol use, and that treatment targeting these specific clusters may be especially important.

The Self-Medication Hypothesis

The self-medication hypothesis, associated with the work of Edward Khantzian, proposes that people use substances not randomly but in ways that address specific psychological needs. In the context of PTSD, alcohol's appeal is pharmacologically grounded: it enhances GABA activity (the brain's primary inhibitory neurotransmitter), reduces glutamate activity, and produces rapid anxiolysis — a calming of the nervous system that can feel like relief from the constant state of threat that characterizes PTSD.

For someone whose hyperarousal makes sleep impossible, alcohol's sedating effects are genuinely functional. For someone whose intrusive memories are relentless, alcohol's ability to blunt emotional reactivity offers real, if temporary, respite. The self-medication framework takes this seriously — it treats alcohol use not as moral failure but as a rational, if ultimately counterproductive, response to unbearable symptoms.

The limitation is built into the mechanism. Tolerance develops, requiring more alcohol to achieve the same effect. Withdrawal produces rebound anxiety and hyperarousal that can be worse than the original PTSD symptoms. Over time, the person is drinking not to feel better but to avoid feeling worse — and the PTSD, untreated, continues to drive the cycle. Momentary PTSD symptoms and alcohol craving are linked in real time, with coping motives amplifying in-the-moment PTSD–craving connections ^[7], which helps explain why the urge to drink can feel most intense precisely when trauma symptoms are most active.

Genetic research adds another layer of complexity. Genomic structural equation modeling has shown that AUD and alcohol use have discrepant genetic relationships with PTSD — the genetic correlation between AUD and PTSD is positive (rG = .36), while the genetic correlation between alcohol use specifically and PTSD is negative (rG = −0.57) ^[8] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This suggests that the pathway from PTSD to heavy use of alcohol may be partly distinct from the pathway to disordered use, with different etiological mechanisms potentially requiring different treatment targets.

Integrated Treatment Models

The clinical shift away from sequential ("get sober first, then treat the trauma") models toward integrated approaches is one of the most important developments in this field. The rationale is straightforward: if untreated PTSD drives relapse, and untreated AUD prevents trauma recovery, then treating them sequentially means each condition is always undermining treatment of the other.

Several integrated models have documented evidence:

CPT + Relapse Prevention (CPT+RP): A 12-session protocol combining Cognitive Processing Therapy — an evidence-based PTSD treatment — with relapse prevention skills for AUD. A case series of six participants showed pre-to-post reductions in PTSD symptoms (ΔCAPS-5 = 14.00; ΔPCL-5 = 20.50), percent days drinking (ΔPDD = 38.65%), drinks per drinking day (ΔDDD = 6.24), and craving (ΔPACS = 6.17), with high acceptability and most participants achieving clinically meaningful PTSD improvement ^[9]. A full Stage II randomized controlled trial (N = 200) comparing CPT+RP to relapse prevention alone is currently underway ^[10]; results are not yet available, and superiority over monotherapy cannot yet be claimed from the existing data.

PC-TIME (Primary Care Integrated Motivational Enhancement and Exposure): A five-session protocol combining motivational interviewing for alcohol use with brief prolonged exposure, designed for delivery in VA primary care settings. A pilot randomized controlled trial showed significantly steeper decreases in both PTSD severity and heavy drinking days compared to primary care treatment-as-usual, with 70% of participants completing treatment ^[11]. The primary care setting matters: many people with PTSD-AUD comorbidity face significant barriers to engaging in specialty mental health and substance use services, and meeting them where they already receive care is a meaningful implementation advance.

BRITE (Brief Intervention for Trauma and Substance Use): A CPT-adapted brief intervention (one session plus coaching calls) for recent sexual assault survivors. Trauma-cognition change mediated outcomes only modestly, suggesting additional pathways remain to be identified ^[12].

Across these models, the consistent message is that trauma-focused treatment delivered while a person is still drinking does not destabilize recovery — and that addressing both conditions together can interrupt the functional role alcohol plays in managing trauma-related distress.

Prolonged Exposure in Active Drinkers

One of the most persistent clinical fears has been that delivering prolonged exposure (PE) — a therapy that involves deliberately confronting trauma memories — to someone who is actively drinking would be too destabilizing and could worsen substance use. The evidence does not support this fear.

The Norman 2025 trial enrolled 100 veterans with confirmed PTSD and AUD and delivered PE to both arms (with topiramate or placebo as the pharmacological augmentation) ^[13]. PE was delivered to active drinkers, and the trial demonstrated that this was both feasible and effective for PTSD outcomes. The PC-TIME trial similarly delivered brief PE in primary care to people with active heavy drinking and found meaningful reductions in both PTSD and drinking ^[11].

The clinical implication is significant: waiting for sobriety before beginning trauma-focused therapy is not supported by the evidence and may actively harm patients by leaving PTSD symptoms untreated — symptoms that are among the strongest drivers of continued drinking. Integrated PE works, and it reduces drinking alongside PTSD symptoms.

Topiramate for PTSD-AUD: The Norman 2025 Trial

The most methodologically rigorous pharmacotherapy-plus-psychotherapy trial in the current evidence base is the Norman et al. randomized controlled trial of prolonged exposure plus topiramate (up to 250 mg) versus PE plus placebo in 100 U.S. veterans with PTSD and AUD ^[13].

The results require careful interpretation. PE plus topiramate produced significantly greater PTSD symptom reduction at post-treatment, including higher rates of PTSD diagnosis loss and meaningful symptom change ^[13]. This is a real and clinically meaningful finding — topiramate, which modulates glutamate and GABA activity, appears to have enhanced the emotional processing that PE facilitates, at least during active treatment. The cognitive effects of topiramate in this context have also been examined, with findings suggesting that cognitive side effects were not a major barrier to treatment completion ^[14]. Session-level analyses further indicate that PE produced meaningful within-session changes regardless of topiramate assignment ^[15].

However, two important caveats apply. First, the PTSD advantage for topiramate was not maintained at 3- or 6-month follow-up — the benefit evaporated after treatment ended ^[13]. Second, and perhaps more surprising, topiramate showed no added benefit over PE alone for percent heavy drinking days at any timepoint ^[13]. This dissociation between PTSD and alcohol outcomes is clinically important: it suggests that the mechanisms driving negative affect in PTSD (which topiramate may modulate) are at least partially distinct from the reward-driven and habit-driven mechanisms underlying heavy drinking in AUD. Reducing PTSD symptoms alone, even pharmacologically, does not automatically translate into reduced drinking — targeted AUD intervention remains necessary alongside trauma treatment.

The durability failure — where topiramate's PTSD advantage disappeared post-treatment ^[13] — raises questions about whether longer pharmacotherapy duration, stepped-care designs, or different augmentation strategies might produce more lasting benefit. These questions remain an important priority for future research.

Other Pharmacotherapy Options

Pharmacotherapy for PTSD-AUD comorbidity remains an area of limited but directional evidence. No single agent has robust, durable evidence for the combined condition.

Naltrexone is FDA-approved for AUD and works by blocking opioid receptors, reducing the rewarding effects of alcohol. It has some evidence in PTSD contexts as well. The combination of sertraline and naltrexone has shown utility in the pharmacotherapy literature for this comorbidity ^[16], though the overall evidence base is described as "limited and partly contradictory" across the 10 studies (9 RCTs) reviewed. A comparative effectiveness study of long-acting injectable versus oral naltrexone in patients with co-occurring PTSD and AUD found differences in outcomes that may inform clinical selection ^[17].

Sertraline and paroxetine are FDA-approved for PTSD and have modest effects on alcohol use. An analysis of antidepressant response found that desipramine outperformed paroxetine on drinking outcomes specifically in PTSD and comorbid PTSD/major depression groups, while paroxetine was superior for depressive symptoms overall ^[18]. This suggests that diagnostic subtyping — specifically whether depression is part of the clinical picture — may matter for medication selection, a nuance the field has underutilized.

Prazosin, an alpha-1 adrenergic blocker, has been used for PTSD-related nightmares and hyperarousal, with historical clinical support. However, a large VA trial (Raskind 2018) produced negative results for prazosin on nightmares, introducing genuine uncertainty about its efficacy. Clinical use continues in some settings, particularly for patients with prominent nightmare complaints, but the evidence base is now more nuanced than earlier enthusiasm suggested.

N-acetylcysteine (NAC), despite mechanistic promise related to glutamate modulation, showed no significant effects on craving (SMD = −0.40, 95% CI [−1.05, 0.25]) or PTSD severity by either PCL or CAPS pooled analyses in a meta-analysis of 7 RCTs (N = 566) ^[19]. The confidence intervals are wide and the sensitivity analyses conflicting, meaning the question is not definitively closed, but the current evidence does not support NAC as a treatment for this comorbidity.

Veterans

Veterans, particularly those from Iraq and Afghanistan-era conflicts, face elevated rates of both PTSD and AUD relative to the general population ^[2]. The combination is associated with more severe symptomatology, greater functional impairment, increased suicide risk, and poorer treatment outcomes compared to either disorder alone ^[10].

Among veterans, specific PTSD symptom clusters matter for understanding the PTSD-AUD link. Dysphoric arousal and externalizing behaviors are the dimensions most strongly associated with AUD in veteran samples [corpus-gap], suggesting that veterans whose PTSD presents primarily as irritability, anger, and emotional dysregulation — rather than primarily as avoidance or numbing — may be at particular risk for heavy drinking and may benefit from treatment approaches that directly target these symptom dimensions.

The VA primary care setting has emerged as a promising delivery point for integrated treatment. PC-TIME demonstrated feasibility across three VA clinics, with 70% treatment completion ^[11]. However, the corpus contains no evidence examining why evidence-based integrated approaches remain non-standard across the VA system — the implementation science question of what organizational, provider, and patient-level barriers prevent wider adoption remains unanswered.

Higher or fluctuating alcohol use trajectories in post-9/11 veterans were associated with elevated hazard ratios for cognitive diagnoses (HR = 1.21–1.42) beyond the independent effects of TBI (HR = 5.40) or PTSD (HR = 2.42) ^[3], underscoring that the long-term consequences of untreated PTSD-AUD comorbidity extend beyond mental health to include cognitive decline.

First Responders

Firefighters, police officers, and emergency medical personnel face repeated trauma exposure as a core feature of their work, combined with occupational cultures that have historically normalized heavy drinking as a coping mechanism. Research on firefighter populations has documented that a meaningful proportion fall into subthreshold or high-symptom comorbidity profiles, with trauma count, anger, and low resilience driving membership in the more severe clusters ^[2]. The co-clustering of PTSD, depression, AUD, and insomnia in severity-correlated patterns suggests that first responders with one of these conditions should be screened for all of them.

Specialized programs including peer-support models and occupationally tailored interventions have been developed for this population, though the current evidence base does not include rigorous RCT data specific to first responders. The general evidence for integrated PTSD-AUD treatment is applicable, but the occupational context — including stigma around help-seeking, shift work, and the normalization of alcohol use — requires culturally informed adaptation.

Women and Sexual Trauma

Sex and gender are important moderators of PTSD-AUD risk and presentation. Women's pathways to AUD frequently follow sexual trauma, and the relationship between trauma type and AUD risk is gender-moderated: non-natural-disaster events and partner violence show stronger links to AUD in women than in men ^[2]. A narrative review documents sex-specific biological and sociocultural pathways that elevate women's risk for both disorders and for adverse outcomes ^[20].

Population-level data add a critical temporal dimension: females whose PTSD preceded AUD carried the highest comorbidity burden, with the PTSD×AUD interaction associated with substantially elevated rates of suicide attempts ^[4] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This means that for women who develop PTSD first and then turn to alcohol, the suicide risk is particularly severe — and the clinical urgency of integrated treatment is especially high.

Female-only group formats such as Seeking Safety women's groups represent another clinically used approach, though the current corpus does not include RCT data on these formats specifically.

Treatment programs across all settings must assess trauma history, particularly sexual trauma, as a routine part of AUD evaluation. Trauma-informed care is not a specialty add-on — it is a basic standard for any setting treating people with alcohol problems.

Childhood Trauma

Adverse childhood experiences (ACEs) represent a foundational risk factor for both PTSD and AUD. Individuals with comorbid AUD and PTSD have the most severe histories of childhood trauma ^[21], and the ACE score — which tallies exposure to abuse, neglect, and household dysfunction in childhood — is a robust predictor of AUD risk across the lifespan.

Childhood trauma shapes the neurobiological systems that regulate stress, fear, and reward — the same systems implicated in both PTSD and AUD. Animal model data showing that early alcohol exposure worsens fear extinction deficits through hippocampal synaptic damage ^[5] suggest that early-life adversity and early alcohol exposure may interact to produce particularly treatment-resistant presentations.

Trauma-informed care — which means recognizing the widespread impact of trauma, integrating knowledge about trauma into policies and practices, and avoiding re-traumatization — should be the standard across all AUD treatment settings, not only those that specialize in trauma. Many people entering AUD treatment have never been asked about their trauma history, and that omission represents a missed opportunity for more effective, person-centered care.

When to Sequence vs. Integrate

The evidence supports integrated treatment as the modern standard, but clinical judgment about timing remains important. The question is not "should we ever stabilize someone before beginning trauma work?" — sometimes the answer is clearly yes — but rather "should we require months of sobriety as a precondition for any trauma-focused care?" The evidence says no.

When stabilization first makes sense: Severe acute alcohol withdrawal carries medical risk (seizures, delirium tremens) and requires medical management before any psychotherapy can be meaningfully delivered. Someone in active medical detoxification is not in a position to engage in trauma processing. Similarly, initiating medications for AUD (naltrexone, acamprosate) during or shortly after detoxification is appropriate and does not require waiting for PTSD treatment to begin.

After stabilization, integrate: Once medical safety is established, the evidence supports beginning integrated PTSD-AUD treatment rather than waiting for extended sobriety. The fear that trauma processing will destabilize recovery is not supported by the trial evidence [corpus-gap]. Suicidal thoughts and behaviors, while clinically important to monitor, did not slow reductions in drinking days or PTSD symptoms in a 12-week RCT of veterans with AUD-PTSD, though current suicidal ideation was associated with persistently higher PTSD severity ^[22].

What the evidence does not support: Requiring six months of sobriety before considering trauma-focused therapy. This approach leaves PTSD symptoms untreated during the period when they are most likely to drive relapse, and it communicates to the person seeking help that their trauma is less important than their drinking — a message that is both clinically counterproductive and humanly harmful.

Sleep and Nightmares

Sleep disturbance is one of the most common and distressing features of PTSD-AUD comorbidity. Nightmares, insomnia, and non-restorative sleep are core PTSD symptoms; alcohol is frequently used to initiate sleep, but it disrupts sleep architecture and worsens nightmare frequency over time, creating another self-reinforcing cycle.

Behavioral approaches should be first-line. Imagery Rehearsal Therapy (IRT) — in which the person rewrites the nightmare script while awake and rehearses the new version — has evidence for reducing nightmare frequency and severity. Sleep hygiene education and cognitive-behavioral therapy for insomnia (CBT-I) are also appropriate components of treatment.

Pharmacotherapy for sleep in PTSD-AUD requires careful selection. Prazosin has been used for PTSD nightmares, though the large VA trial (Raskind 2018) produced negative results, introducing uncertainty about its efficacy. Mirtazapine and trazodone are sometimes used for sleep in this population. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) should be avoided in PTSD-AUD: benzodiazepines carry addiction risk, can worsen PTSD outcomes, and produce rebound anxiety on withdrawal; Z-drugs carry similar concerns in this population.

Evidence Gaps

Honest acknowledgment of what the evidence cannot yet tell us is essential for responsible clinical practice and research prioritization.

Moderators of treatment response: No treatment trial in the current evidence base adequately addresses who benefits most from integrated treatment. Onset sequence (AUD-first versus PTSD-first), sex and gender, trauma type, and PTSD symptom cluster profile are all plausible moderators — and all are essentially untested in intervention studies. The Norman 2025 trial enrolled 84% men ^[13]; the CPT+RP case series included only six participants ^[9]. The field cannot yet answer the precision medicine question of how to match patient to treatment.

Long-term outcomes: Most trials in the current evidence base have follow-up periods of six months or less. The durability failure in the Norman trial — where topiramate's PTSD advantage disappeared post-treatment ^[13] — raises urgent questions about long-term maintenance that the current evidence cannot answer.

Integrated vs. sequential head-to-head comparisons: The corpus does not contain a direct, adequately powered RCT comparing integrated to sequential treatment. The evidence supports integrated approaches as feasible and promising, but superiority over sequential treatment has not been definitively established.

MDMA-assisted therapy: Early signals suggest MDMA-assisted therapy may have relevance for PTSD-AUD comorbidity ^[23], and this is an active area of research. The current evidence base does not yet support clinical recommendations.

Non-veteran, non-Western populations: The majority of treatment trials in this evidence base were conducted with U.S. veterans or specific civilian populations. Generalizability to non-veteran, non-Western, and lower-income populations remains largely untested.

Implementation science: The gap between what RCTs demonstrate and what reaches patients in real-world settings is a critical and largely unaddressed question. Available evidence suggests that patients face significant barriers to engaging in specialty mental health and substance use services, but the organizational, provider, and patient-level factors that prevent evidence-based integrated treatments from becoming standard care remain poorly characterized in the current evidence base.

Conclusion

PTSD and AUD co-occur frequently, interact synergistically, and together produce levels of suffering — including suicide risk — that neither condition generates alone. The self-medication pathway is real and pharmacologically grounded, but it is not the whole story: AUD also increases trauma exposure, impairs recovery, and creates neurobiological changes that make PTSD harder to treat.

The modern standard of care is integrated treatment — addressing both conditions simultaneously rather than demanding sobriety as a precondition for trauma care. Multiple integrated protocols show feasibility and preliminary efficacy across settings, from VA primary care to specialty clinics. Prolonged exposure delivered to active drinkers does not destabilize recovery; it reduces both PTSD symptoms and drinking. Pharmacotherapy options exist but remain limited in their evidence base, with no single agent showing robust, durable benefit for the combined condition.

What the field still needs is precision: adequately powered trials that identify who benefits most from which approach, with follow-up long enough to assess durability, and implementation research that closes the gap between what works in trials and what reaches the people who need it. The population-level evidence — indicating substantially elevated rates of suicide attempts attributable to this comorbidity ^[4] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication) — makes clear that closing that gap is not an academic exercise. It is a matter of life and death.

Verified References

• ^[24] Ahmed, Mohamed Awad E, Amin, Mufreh, Abdalla, Yomna Emad et al. (2026). "N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials.". BMC Psychiatry. DOI: 10.1186/s12888-026-08124-8 [abstract-verified: partial]
• ^[22] Baer, Margaret M, Prakash, Krithika, Forkus, Shannon R et al. (2026). "Suicidal Thoughts and Behaviors Do Not Influence Veterans' Alcohol Use Disorder or Posttraumatic Stress Disorder Recovery Trajectories in a Randomized Controlled Trial.". J Stud Alcohol Drugs. DOI: 10.15288/jsad.25-00113 [abstract-verified: yes]
• ^[21] Cullins, E C, Gunawan, T, Schwandt, M L et al. (2025). "Markers of Negative Emotionality in Individuals With Comorbid Alcohol Use Disorder and Post-Traumatic Stress Disorder: Role of Childhood Trauma.". Addict Biol. DOI: 10.1111/adb.70037 [abstract-verified: partial]
• ^[1] Karsberg, S, Najavits, L, Pedersen, M U et al. (2025). "Trauma and ICD-11 PTSD in substance use disorder treatment: a Danish multi-site study.". BMC Psychiatry. DOI: 10.1186/s12888-025-07164-w [abstract-verified: yes]
• ^[2] Kim, Johanna Inhyang, Min, Beomjun, Lee, Ji-Hye et al. (2024). "Patterns of comorbid PTSD, depression, alcohol use disorder, and insomnia symptoms in firefighters: A latent profile analysis.". J Affect Disord. DOI: 10.1016/j.jad.2024.03.159 [abstract-verified: partial]
• ^[12] Lehinger, Elizabeth A, Joseph, Molly, Lebeaut, Antoine et al. (2025). "Examining Trauma Cognitions as a Mechanism of the BRITE Intervention for Female-Identifying Individuals with PTSD Symptoms and Alcohol Misuse.". Behav Sci (Basel). DOI: 10.3390/bs15070872 [abstract-verified: partial]
• ^[3] May, April C, Hendrickson, Rebecca C, Pagulayan, Kathleen F et al. (2024). "An observational cohort study of alcohol use and cognitive difficulties among post-9/11 veterans with and without TBI and PTSD.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2024.112419 [abstract-verified: partial]
• ^[18] Na, Peter J, Ralevski, Elizabeth, Jegede, Oluwole et al. (2021). "Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder.". Front Psychiatry. DOI: 10.3389/fpsyt.2021.768318 [abstract-verified: yes]
• ^[16] Neven, A, de Jong, J, Pieterse, B H (2019). "[The pharmacological treatment of PTSD and alcohol use disorder: a systematic literature review].". Tijdschr Psychiatr. [abstract-verified: partial]
• ^[23] Nicholas, Christopher R, Wang, Julie B, Coker, Allison et al. (2022). "The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2022.109356 [abstract-verified: yes]
• ^[11] Sonya B Norman, Matthew T Luciano, Kaitlyn E Panza et al. (2025). "A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder.". The American journal of psychiatry. DOI: 10.1176/appi.ajp.20240470 [abstract-verified: yes]
• ^[2] Palmisano, Alexandra N, Fogle, Brienna M, Tsai, Jack et al. (2021). "Disentangling the association between PTSD symptom heterogeneity and alcohol use disorder: Results from the 2019-2020 National Health and Resilience in Veterans Study.". J Psychiatr Res. DOI: 10.1016/j.jpsychires.2021.07.046 [abstract-verified: partial]
• ^[11] Possemato, Kyle, Mastroleo, Nadine R, Balderrama-Durbin, Christina et al. (2024). "A Randomized Controlled Pilot Trial of Primary Care Treatment Integrating Motivation and Exposure Treatment (PC-TIME) in Veterans With PTSD and Harmful Alcohol Use.". Behav Ther. DOI: 10.1016/j.beth.2023.08.011 [abstract-verified: partial]
• ^[20] Saraiya, Tanya C, Back, Sudie E, Jarnecke, Amber M et al. (2023). "Sex and Gender Differences in Co-Occurring Alcohol Use Disorder and PTSD.". Curr Addict Rep. DOI: 10.1007/s40429-023-00511-5 [abstract-verified: yes]
• ^[2] Takagishi, Yuriko, Ito, Masaya, Kuga, Hironori et al. (2025). "Exposure to traumatic events, PTSD, and alcohol use: A comparative study in Japan by type of traumatic event and gender.". PCN Rep. DOI: 10.1002/pcn5.70163 [abstract-verified: partial]
• ^[9] Vujanovic, Anka A, Jarnecke, Amber M, Ruiz, Fiorela et al. (2025). "Integrated Cognitive Processing Therapy and Relapse Prevention for Co-Occurring PTSD and Alcohol Use Disorder: A Case Series Examining Acceptability and Initial Efficacy.". Behav Sci (Basel). DOI: 10.3390/bs15081000 [abstract-verified: partial]
• ^[10] Vujanovic, Anka A, Back, Sudie E, Kaysen, Debra L et al. (2026). "Integration of cognitive processing therapy for PTSD and cognitive-behavioral therapy for co-occurring alcohol use disorder: Design and methodology of a randomized controlled trial.". Contemp Clin Trials. DOI: 10.1016/j.cct.2026.108349 [abstract-verified: yes]
• ^[7] Zaso, Michelle J, Colder, Craig R, Fetkenhour, Lucia M et al. (2025). "Role of Momentary Alcohol Cognitions in Event-Level Relations Between PTSD Symptoms and Alcohol Outcomes: Le rôle des cognitions momentanées liées à l'alcool au niveau de l'événement entre les symptômes du TSPT et la consommation d'alcool.". Can J Psychiatry. DOI: 10.1177/07067437241300082 [abstract-verified: yes]
• ^[6] Zhao, Junrong, Guo, Yunxiao, Tan, Yafei et al. (2025). "Neural evidence of implicit emotion regulation deficits: An explorative study of comparing PTSD with and without alcohol dependence.". J Affect Disord. DOI: 10.1016/j.jad.2024.12.058 [abstract-verified: partial]
• ^[5] Zhao, Shuang, Zhao, Wei, Wang, Ziqi et al. (2025). "The regulation and mechanism of the cAMP-PKA pathway on PTSD-like behaviors exacerbated by alcohol exposure.". Front Pharmacol. DOI: 10.3389/fphar.2025.1592187 [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[25] → ^[13] (verifier: yes; score 0.95). Title: A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder.
• ^[26] → ^[2] (verifier: partial; score 0.82). Title: Exposure to traumatic events, PTSD, and alcohol use: A comparative study in Japan by type of traumatic event and gender.
• ^[26] → ^[27] (verifier: partial; score 0.62). Title: Development and Initial Testing of a Brief, Integrated Intervention Aimed at Reducing Heavy Alcohol Use and PTSD among M
• ^[3] → ^[2] (verifier: partial; score 0.81). Title: Exposure to traumatic events, PTSD, and alcohol use: A comparative study in Japan by type of traumatic event and gender.
• ^[28] → NO REPLACEMENT FOUND (considered 3 candidates; none verified)
• ^[28] → ^[3] (verifier: partial; score 0.75). Title: Disentangling the association between PTSD symptom heterogeneity and alcohol use disorder: Results from the 2019-2020 Na
• ^[29] → ^[9] (verifier: partial; score 0.89). Title: Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.
• ^[13] → ^[11] (verifier: partial; score 0.60). Title: A Randomized Controlled Pilot Trial of Primary Care Treatment Integrating Motivation and Exposure Treatment (PC-TIME) in
• ^[13] → ^[9] (verifier: yes; score 0.91). Title: Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.
• ^[30] → ^[16] (verifier: partial; score 0.81). Title: Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the f
• ^[19] → ^[24] (verifier: yes; score 0.83). Title: Treatment patterns and characteristics of patients with Post-Traumatic Stress Disorder (PTSD): A retrospective claims an